<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081534</url>
  </required_header>
  <id_info>
    <org_study_id>D5613C00001</org_study_id>
    <nct_id>NCT02081534</nct_id>
  </id_info>
  <brief_title>Dose Finding Study to Treat High Phosphate Levels in the Blood.</brief_title>
  <official_title>A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks
      treatment period
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening period of approximately 1 week, a wash out period of up to
      3 weeks, where existing phosphate lowering medication is withheld, a 4-week treatment period
      and a follow-up period of up to 2 weeks, during which patients are put back on their pre
      washout phosphate lowering medication.

      The wash out period will be either 1 week, 2 weeks or 3 weeks depending on the increase in
      s-phosphate levels.

      There are 7 parallel treatment arms in the study with bid and od treatment regimens.

      Laboratory efficacy endpoints and safety assessments will be evaluated at various times
      throughout the study.

      The target population of the study is: male or female patients, above18 years of age with End
      Stage Renal Disease (ESRD) on chronic maintenance hemodialysis (HD) 3 times a week for a
      minimum of 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum phosphate levels</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients reaching S-phosphate goal</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>Comparison of the effect of AZD1722 versus placebo on the number of patients reaching serum phosphate goal levels defined as &lt; 5.5 mg/dl (1.78 mmol/L) during 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in calcium x phosphorus product</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>Change from baseline (end of wash out) in calcium x phosphorus product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre wash out in S-phosphate levels</measure>
    <time_frame>Pre wash out to end of treatment (Day 29)</time_frame>
    <description>Comparison of the effect of AZD1722 versus pre wash out phosphate-lowering treatment, by comparing serum phosphate levels during AZD1722 treatment to pre wash out levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD1722</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>To evaluate the safety and tolerability of AZD1722 as assessed by adverse event recording, vital signs, 12-lead electrocardiogram, physical examination, and safety laboratory monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose response relationship</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>To characterize the dose response relationship of AZD1722 on serum phosphate levels</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">597</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>1 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg od</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg AZD1722 od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg od</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg AZD1722 od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (double dummy technique)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722</intervention_name>
    <description>AZD1722, oral tablet</description>
    <arm_group_label>1 mg bid</arm_group_label>
    <arm_group_label>3 mg bid</arm_group_label>
    <arm_group_label>10 mg bid</arm_group_label>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_label>3 mg od</arm_group_label>
    <arm_group_label>30 mg od</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo bid, double dummy technique</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females and males aged â‰¥18 years

          2. Chronic maintenance hemodialysis 3 x/week for a at least 3 months

          3. Prescribed and taking at least 3 doses of phosphate binder per day

          4. Serum phosphate levels should be between 3.5 and 8.0 mg/dL ; 1.13 mmol/L and 2.58
             mmol/L (inclusive) at screening

          5. Total serum calcium levels 2.0 - 2.6 mmol/L inclusive at screening

          6. For randomization in the study, after up to 3 weeks wash out of phosphate binders,
             patients must have serum phosphate levels of at least 6. 0 mg/dL (1.94 mmol/L) but
             below 10 mg/dL (3.23 mmol/L) and have had an increase of at least 1.5 mg/dL (0.48
             mmol/L) vs pre wash out

        Exclusion Criteria:

          1. Severe hyperphosphatemia defined as &gt;10 mg/dL on Phosphate-binders at all time points
             during clinical routine monitoring for the 3 preceding months before screening visit.

          2. Serum parathyroid hormone &gt;1200 pg/mL

          3. Significant metabolic acidosis

          4. Clinical signs of hypovolemia at randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey A Block, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Nephrology PC, Denver, CO 80230</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maspeth</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dzialdowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zary</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hlohovec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puchov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Senica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S-phosphate, hyperphosphatemia, hemodialysis, ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

